Podcasts

Exploring Second-Generation BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Dr. Adam Kittai (Icahn School of Medicine, Mount Sinai, New York)

Dr. Kittai is an Associate Professor at the Icahn School of Medicine at Mount Sinai in New York, NY where he is the Assistant Director of Lymphoma Clinical Research and CLL Clinical Research Leader. His clinical and research focus is on Chronic Lymphocytic Leukemia, Richter Transformation and related disorders. He is the primary investigator of multiple investigator-initiated trials exploring the use of small molecule inhibitors with novel designs and deploying cellular therapies for CLL and Richter transformation.

This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with AstraZeneca.

NS ID 4610-Revision date 08/2024-WEB Local code 1506

SUBSCRIBE TO BJH HEMATALKS SERIES